181 related articles for article (PubMed ID: 34536950)
1. ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen.
Wang L; Lyu Y; Li Y; Li K; Wen H; Feng C; Li N
Aging (Albany NY); 2021 Sep; 13(18):22286-22297. PubMed ID: 34536950
[TBL] [Abstract][Full Text] [Related]
2. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
[TBL] [Abstract][Full Text] [Related]
3. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
4. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
5. FSCN1 as a new druggable target in adrenocortical carcinoma.
Ruggiero C; Tamburello M; Rossini E; Zini S; Durand N; Cantini G; Cioppi F; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Landwehr LS; Weigand I; Kurlbaum M; Zizioli D; Turtoi A; Yang S; Berruti A; Luconi M; Sigala S; Lalli E
Int J Cancer; 2023 Jul; 153(1):210-223. PubMed ID: 36971100
[TBL] [Abstract][Full Text] [Related]
6. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
7. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
8. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
[TBL] [Abstract][Full Text] [Related]
9. MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.
Creemers SG; van Koetsveld PM; De Herder WW; Dogan F; Franssen GJH; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Mar; 26(3):367-378. PubMed ID: 30650062
[TBL] [Abstract][Full Text] [Related]
10. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
12. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic treatment of adrenocortical carcinoma.
Ahlman H; Khorram-Manesh A; Jansson S; Wängberg B; Nilsson O; Jacobsson CE; Lindstedt S
World J Surg; 2001 Jul; 25(7):927-33. PubMed ID: 11572034
[TBL] [Abstract][Full Text] [Related]
14. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target.
Demeure MJ; Coan KE; Grant CS; Komorowski RA; Stephan E; Sinari S; Mount D; Bussey KJ
Surgery; 2013 Dec; 154(6):1405-16; discussion 1416. PubMed ID: 24238056
[TBL] [Abstract][Full Text] [Related]
15. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
[TBL] [Abstract][Full Text] [Related]
16. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
Ren L; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang J
J Transl Med; 2022 Oct; 20(1):444. PubMed ID: 36184616
[TBL] [Abstract][Full Text] [Related]
17. Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo.
Hasanovic A; Ruggiero C; Jung S; Rapa I; Signetti L; Ben Hadj M; Terzolo M; Beuschlein F; Volante M; Hantel C; Lalli E; Mus-Veteau I
Int J Cancer; 2018 Jul; 143(1):199-211. PubMed ID: 29411361
[TBL] [Abstract][Full Text] [Related]
18. Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study.
Wu L; Huang X; Kuang Y; Xing Z; Deng X; Luo Z
Drug Des Devel Ther; 2019; 13():2787-2798. PubMed ID: 31496655
[TBL] [Abstract][Full Text] [Related]
19. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
[TBL] [Abstract][Full Text] [Related]
20. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
Brown TC; Nicolson NG; Stenman A; Juhlin CC; Gibson CE; Callender GG; Korah R; Carling T
J Am Coll Surg; 2019 Sep; 229(3):305-315. PubMed ID: 31034883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]